证券研究报告 | 2025年04月15日 澳华内镜（688212.SH） 优于大市 国内收入增速放缓，海外业务增速亮眼 收入端稳健，利润端承压。2024 年公司实现营收 7.50 亿元（+10.54%）， 归母净利润 0.21 亿元（-63.68%），扣非归母净利润-0.06 亿元 （-114.13%）。24Q4 单季营收 2.49 亿元（-0.20%），归母净利润-0.16 亿元（-228.60%），扣非归母净利润-0.21 亿元（-392.07%）。2024 年 收入增长较 2023 年放缓，主要系受国内招采活动减少的影响，国内业 务收入增长有限。利润端承压，主要系公司持续加大研发及市场投入力 度，以及计提了坏账损失、商誉减值所致。 毛利率略有下滑，费用率上升。2024 年毛利率 68.12%，表观毛利率下降 5.66pp，主要系会计准则变更，保证类质保费用从销售费用调整至营业 成本所致，调整后主营业务毛利率下滑 1.57pp，预计系毛利率较低的海 外业务占比提升所致。销售费用率 33.38%（+3.16pp），管理费用率 14.48% （+1.08pp），研发费用率 21.83%（+0.15pp），财务 ...

证券研究报告 医药生物 | 医疗器械 非金融|公司点评报告 hyzqdatemark 2025 年 04 月 16 日 证券分析师 刘闯 SAC：S1350524030002 liuchuang@huayuanstock.com 林海霖 SAC：S1350524050002 linhailin@huayuanstock.com 市场表现： | 基本数据 | | 年 | 04 | 月 15 | | | | 2025 | 日 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 收盘价（元） | | | | | | | 41.14 | | | | 一 年 内 高 低 | 最 | | | | 最 | / | | | | | 总市值（百万元） | | | | | | | 5,540.13 | | | | 流通市值（百万元） | | | | | | | 5,540.13 | | | | 总股本（百万股） | | | | | | | 134.67 | | | | 资产负债率（%） | | | | | | | 21.06 | | | | 每股净资 ...

Group 1: Company Insights - Aohua Endoscope reported a revenue of 750 million yuan in 2024, a year-on-year increase of 10.54%, but a net profit of 21.01 million yuan, down 63.68% year-on-year [3][4] - The company faced challenges due to reduced domestic procurement activities and increased expenses in R&D and marketing, which outpaced revenue growth [4] - Aohua's core product, the AQ-300 4K endoscope system, is gaining acceptance in hospitals, with expectations for revenue growth in the coming years, projecting revenues of 892 million, 1.072 billion, and 1.26 billion yuan from 2025 to 2027 [5] Group 2: Industry Trends - The U.S. has implemented increased tariffs, causing significant fluctuations in global assets, with a 10% minimum baseline tariff affecting various trade partners [7][8] - The domestic macroeconomic sentiment is influenced by overseas developments, with China's foreign exchange reserves reaching 3.24067 trillion USD, a 0.4% increase [8] - The wind power industry is expected to see a demand increase of 34% in 2025, with domestic wind turbine demand projected to reach 124 GW [21][22] - The automotive sector is entering a phase of increased sales and technological advancements, with new models from various manufacturers being launched [16][19] Group 3: Financial Performance - Shengnong Development achieved a revenue of 18.586 billion yuan in 2024, a year-on-year increase of 0.53%, and a net profit of 724 million yuan, up 9.03% [12][13] - Jinhuijiu reported a revenue of 1.108 billion yuan in Q1 2025, a year-on-year increase of 3.04%, with a net profit of 234 million yuan, up 5.77% [25][26] - XJ Electric reported a revenue of 17.1 billion yuan in 2024, a slight increase of 0.2%, with a net profit of 1.12 billion yuan, up 11% [29][30] Group 4: Market Opportunities - The automotive sector is expected to benefit from policies promoting vehicle upgrades, with a focus on high-end models and advanced driving technologies [19][20] - New energy and precision bearing markets are anticipated to grow, with XJ Electric and Xinqianglian positioned to capitalize on these trends [21][22][29] - The semiconductor industry is likely to see accelerated domestic production due to tariff pressures, presenting investment opportunities in related sectors [34][36]

Investment Rating - The investment rating for the company is "Outperform the Market" [5][21][22] Core Views - The company's revenue growth is stable, but profit is under pressure due to increased R&D and marketing investments, as well as provisions for bad debts and goodwill impairment [1][8] - The gross margin has slightly declined, with an increase in expense ratios, primarily due to changes in accounting standards and a higher proportion of lower-margin overseas business [2][14] - The company is experiencing a slowdown in domestic revenue growth due to reduced procurement activities, while overseas revenue is showing strong growth [1][18] Financial Performance Summary - In 2024, the company achieved revenue of 750 million yuan (+10.54%) and a net profit of 21 million yuan (-63.68%), with a non-recurring net profit of -6 million yuan (-114.13%) [1][4] - The gross margin for 2024 is 68.12%, with a decline of 5.66 percentage points, mainly due to accounting changes [2][14] - The company plans to increase revenue to 860 million yuan in 2025, with a projected growth rate of 15% [3][21] Market and Product Development - The company is focusing on promoting the AQ-300 4K ultra-high-definition endoscope system, with steady growth in the installation of mid-to-high-end products [2][18] - In 2024, overseas revenue reached 161 million yuan, a year-on-year increase of 42.70%, accounting for 22% of total revenue [2][18] - The company is expected to benefit from a recovery in the bidding environment starting in 2025, as the industry adjusts to regulatory changes [3][21]

【投资要点】 业绩表现：2024 年，公司实现营业收入7.5 亿元(yoy+10.54%)；实现归母净利润0.21 亿元(yoy- 63.68%)；扣非归母净利-0.06 亿元(yoy-114.13%)。 AQ-300 入院顺利带动设备收入增长，海外业务进展顺利。分业务来看，内窥镜设备实现营收7.14亿元 （yoy+14.72%）；诊疗耗材实现营收0.21亿元（yoy-50.63%）；内窥镜维修服务实现营收0.13 亿元 （yoy+3.31%）。 设备业务的增长主要系AQ-300 装机量稳步提升，2024 年中高端机型主机、镜体在三级医院装机（含中 标）量分别为137 台、522 根，装机（含中标）三级医院达 116 家。分地区来看，2024 年公司国内业务 实现营收5.87 亿（yoy+3.93%），海外业务实现营收1.61 亿元（yoy+42.70%），公司海外市场的产品准 入及市场推广顺利推进，海外品牌影响力持续提升带动海外收入快速增长，国内业务则受到招采活动减 少的影响增长有限。 短期盈利能力有所波动，长期竞争力有望进一步提升。2024 年公司销售毛利率为68.12% (yoy-5.66pct ）； ...

Investment Rating - The industry investment rating is "Outperform the Market" and is maintained [2][50]. Core Viewpoints - The FDA's recent decision to gradually eliminate animal testing requirements for monoclonal antibodies and other drugs is expected to benefit AI-driven drug development, potentially accelerating new drug approvals and reducing R&D costs [5][6][14][16]. - The pharmaceutical and biotechnology sector experienced a decline of 5.61% this week, underperforming the CSI 300 index by 2.73 percentage points, ranking 22nd among 31 sub-industries [19][24]. Summary by Sections Weekly Insights - The FDA's announcement on April 11, 2025, aims to replace animal testing with more effective and human-relevant methods, which could enhance drug safety and lower costs [14][15]. - The shift is anticipated to accelerate drug development timelines and improve success rates, particularly benefiting companies involved in AI drug development such as Jingtai Holdings and Chengdu Xian Dao [6][17]. Subsector Performance - The blood products sector saw the highest increase this week, rising by 4.06%, while the medical outsourcing sector faced the largest decline at 16.04% [7][23]. - The medical device sector decreased by 2.62%, and the traditional Chinese medicine sector fell by 3.35% [7][23]. Recommended and Benefiting Stocks - Recommended stocks include Weidian Physiotherapy, Maipu Medical, and Yingke Medical [8][31]. - Benefiting stocks from the FDA policy change include Jingtai Holdings, Chengdu Xian Dao, and Hongbo Pharmaceutical [6][17]. Detailed Subsector Analysis - **Medical Devices**: The sector is expected to benefit from the "old-for-new" policy and increased procurement activities in Q2 2025, with a current P/E ratio of 32.15, indicating potential for valuation growth [27][29]. - **Medical Consumables**: This sector is under pressure due to US-China tariff impacts, but certain segments are expected to perform well due to high growth potential and improved conditions [30]. - **IVD Sector**: The IVD sector is projected to recover as AI technologies enhance diagnostic capabilities, despite current pressures from procurement policies [33]. - **Blood Products**: The sector is expected to benefit from rising domestic production and increased focus on local sourcing due to tariff impacts [35]. - **Retail Pharmacy**: The offline pharmacy sector is seeing a recovery in customer traffic and profitability, with major players expected to leverage AI for operational efficiency [37][38].

Investment Rating - The industry investment rating is "Outperform the Market" and is maintained [2] Core Viewpoints - The FDA's recent decision to gradually eliminate animal testing requirements for monoclonal antibodies and other drugs is expected to benefit AI-driven drug development, potentially accelerating new drug approvals and reducing R&D costs [5][6][14][16] - The pharmaceutical and biotechnology sector experienced a decline of 5.61% this week, underperforming the CSI 300 index by 2.73 percentage points [19][24] - The blood products sector showed the highest increase this week, rising by 4.06%, while the medical outsourcing sector faced the largest decline, dropping by 16.04% [7][19][23] Summary by Sections Weekly Insights - The FDA's announcement on April 11, 2025, aims to replace animal testing with more effective human-relevant methods in drug development, which could enhance drug safety and lower costs [14][15] - The pharmaceutical sector's performance this week was marked by significant declines across various sub-sectors, with blood products being the only one to gain [19][23] Sub-sector Performance - Blood products increased by 4.06%, while medical outsourcing fell by 16.04%, indicating a significant divergence in performance among sub-sectors [7][19][23] - The medical device sector's P/E ratio is currently at 32.15, suggesting potential for valuation increases [27] - The IVD sector is also seen as having room for valuation growth, with a current P/E of 21.89 [33] Recommended and Benefiting Stocks - Recommended stocks include Microelectrophysiology, Maipu Medical, and Yingke Medical, among others [8][31][38] - Benefiting stocks from the FDA's policy change include Jingtai Holdings, Chengdu Xian Dao, and Hongbo Pharmaceutical [6][17] Market Trends - The report highlights a structural investment opportunity in the pharmaceutical sector, driven by policy support and AI-enabled R&D [26] - The report notes that the medical device sector is expected to benefit from upcoming procurement policies and a low base effect in Q2 2025 [27][29]

澳华内镜（ [Table_StockNameRptType] 688212） 公司点评 国内市场受行业影响增速放缓，海外市场增长亮眼 | [Table_Rank] | 投资评级：买入（维持） | | | --- | --- | --- | | 报告日期： | 2025-04-14 | | | [Table_BaseData] 收盘价（元） | | 41.50 | | 近 12 个月最高/最低（元） | 59.00/31.51 | | --- | --- | | 总股本（百万股） | 135 | | 流通股本（百万股） | 135 | | 流通股比例（%） | 100.00 | | 总市值（亿元） | 56 | | 流通市值（亿元） | 56 | [Table_CompanyReport] 相关报告 1.【华安医药】公司点评：澳华内镜 （688212）：收入短期承压，期待 2024Q4 改善 2024-10-29 2.【华安医药】公司点评：澳华内镜 （688212）：2024H1 业绩符合预期， 期待下半年招标恢复 2024-08-26 主要观点： [➢Table_Summary] 事件： 公司发布 2024 ...

Investment Rating - Investment Rating: Buy (Maintained) [1] Core Views - The company reported a total revenue of 750 million yuan in 2024, representing a year-on-year growth of 10.54%, while net profit decreased by 63.68% to 21.01 million yuan [4][6] - Domestic revenue faced pressure in 2024, with approximately 586 million yuan, a year-on-year increase of about 4%, while overseas revenue grew significantly by approximately 42.7% to 161 million yuan [6][10] - The company plans to increase revenue to 844 million yuan, 1.06 billion yuan, and 1.33 billion yuan in 2025, 2026, and 2027, respectively, with expected year-on-year growth rates of 12.5%, 25.7%, and 25.8% [10][12] Summary by Sections Financial Performance - In 2024, the company achieved total revenue of 750 million yuan, with a net profit of 21 million yuan and a basic earnings per share (EPS) of 0.16 yuan [4][5] - The company declared a cash dividend of 0.80 yuan per 10 shares, totaling 10.72 million yuan, which accounts for approximately 51% of net profit [4] Domestic and Overseas Market Analysis - Domestic revenue growth was constrained due to industry factors, while overseas markets showed strong growth [6] - The company’s domestic market is expected to recover as industry procurement resumes and inventory levels decrease [6] - The overseas revenue growth was driven by successful market entry and brand influence, with a gross margin of 58.15% in 2024 [6][10] Research and Development - The company increased R&D expenditure to 163.6 million yuan in 2024, accounting for 21.83% of total revenue, with significant advancements in product lines [7] - New product launches include electronic endoscopes and high-definition systems, enhancing diagnostic capabilities [7][9] Future Projections - Revenue projections for 2025-2027 are 844 million yuan, 1.06 billion yuan, and 1.33 billion yuan, with corresponding net profits of 54 million yuan, 96 million yuan, and 144 million yuan [10][12] - The expected EPS for 2025, 2026, and 2027 are approximately 0.40 yuan, 0.71 yuan, and 1.07 yuan, with P/E ratios of 102, 58, and 39, respectively [10][12]

Group 1 - The Shenwan Pharmaceutical Index declined by 5.61% this week, underperforming the CSI 300 Index which fell by 2.87%, ranking 22nd among 31 primary industry indices [1] - As of April 11, 2025, the price-to-earnings (PE) ratio for the pharmaceutical and biotechnology industry is 25.78 times, compared to 11.50 times for the CSI 300 Index, indicating a valuation premium of 124.23% for the pharmaceutical sector, which remains at a historical low [1] Group 2 - The recent changes in U.S. tariff policy, which exempt certain categories of goods from additional tariffs, are seen as a measure to ease U.S.-China trade tensions [2] - The exemption applies to all countries subject to "reciprocal tariffs," allowing products correctly classified under specified HTSUS numbers to benefit from a standard additional tariff of 10% instead of higher rates [2] Group 3 - The easing of tariff pressures is expected to benefit China's electronic and semiconductor supply chains, reflecting the strong competitiveness and cost-effectiveness of Chinese manufacturing [3] - The pharmaceutical industry in China also demonstrates similar supply chain capabilities, indicating a strong global reliance on China's pharmaceutical manufacturing, which reduces the likelihood of imposing high tariffs on drugs [3] Group 4 - The latest tariff policy significantly alleviates export chain pressures, with a focus on investment opportunities in the CXO, API, generic drugs, and medical device sectors [4] - Recommended companies include WuXi AppTec, WuXi Biologics, and others in the CXO chain, as well as Huahai Pharmaceutical and others in the API and generic drug sectors [4]